hotspot -WSS

hotspot

author：comprehensive 2025-08-11 08:00:27 - browse：2

An effective treatment for Alzheimer’s disease has long been a holy grail in the pharmaceutical industry. In early June, some hope appeared when the FDA agreed that the anti-amyloid antibody lecanemab (to be sold by Eisai as Leqembi) outperformed placebo in trials. It is expected to receive full approval by July 6.

But this may not necessarily be purely good news.

On the latest episode of the “First Opinion Podcast,” physician and professor Jason Karlawish argues that lecanemab and other promising new drugs, such as donanemab, will introduce complicated issues into the field of Alzheimer’s care. These medications require a great deal of testing and patient monitoring, trained physicians, and other resources in a system that is already stretched thin.

“Dr. Karlawish’s dream of reason would be … a training module for physicians to learn the key things they need to learn and then self-assess their comfort with the drug,” Karlawish said. “But that’s Karlawish’s dream of reason in a world that seems increasingly less reasonable sometimes.”

Karlawish is a professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine. The conversation is based off his recent First Opinion, “The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab.“

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： What does generative AI mean for health care? We asked experts
Next article： STAT's guide to the next generation of CAR

leisure time

WSS

The battle over the Brookhaven Landfill on Long Island

Donald Trump's relentless attacks on special counsel Jack Smith

Doctor appointment wait times are getting worse

A new study asks: Are we harming blood donors by taking blood?

Van's Gluten Free Original Waffles recalled for possible wheat allergen

Ukraine, Russia accuse each other of planning to attack Europe's biggest nuclear plant

focus

hotspot

leisure time

As demand for Covid shots wanes, Moderna seeks its next success

Disclosing genetic information: not as worrisome as once feared

Tori Bowie and the unacceptable rates of Black maternal death

Why we need to separate burnout from moral injury in health care

Dobbs anniversary: the lost opportunity of abortion as health care

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Dobbs anniversary: the lost opportunity of abortion as health care

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

Malaria cases in Florida and Texas: Here’s what you need to know

Why are elite athletes different? Take a look at their microbes

leisure time

Meta looks to target Twitter with a rival app called Threads

Colonoscopy at 40? Study finds a possible benefit

When is a doctor not a doctor? Try when patients address women doctors

Can food be medicine? And other questions about a new push

Why are elite athletes different? Take a look at their microbes

Gene therapy has helped boys walk. Can scientists keep it that way?

focus

leisure time

knowledge

Wikipedia